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Abstract
Introduction: In murine breast cancer models, the two interferon-gamma (IFN-g) inducible chemokines and CXC-
chemokine receptor 3 (CXCR3) receptor ligands, monokine induced by g-interferon (CXCL9) and interferon-g-
inducible protein-10 (CXCL10) impair tumor growth and metastasis formation through recruitment of natural killer
(NK) cells and tumor-suppressive T lymphocytes. In human breast cancer, CXCL9 mRNA overexpression correlates
with the number of tumor infiltrating lymphocytes and predicts response to different chemotherapeutic regimens.
Raising the intratumoral CXCR3 ligand concentration is therefore a possible way to enhance immune intervention
in breast cancer. Little is known, however, about expression levels and regulation of these chemokines in human
breast cancer. Since the inhibition of cyclooxygenases (COX) has been shown to reduce tumor growth and
incidence of metastases in a lymphocytic and IFN-g dependent manner, we argued that COX isoenzymes are a
pharmacologic target to increase intratumoral CXCR3 ligand concentration in human breast cancer.
Methods: CXCL9 was visualized in breast cancer specimens by immunohistochemistry, expression levels of CXCL9
and cyclooxygenases were determined by ELISA and western blotting, respectively. For regulation studies, Michigan
Cancer Foundation-7 (MCF-7) and M.D. Anderson - Metastatic Breast 231 (MDA-MB 231) breast cancer cells were
stimulated with IFN-g with or without prostaglandin E2 (PGE2) or COX inhibitors (indomethacin, acetylsalicylic acid
(ASA), celecoxib). CXCR3 ligand release from cells was measured by ELISA.
Results: Within the tumor microenvironment, cancer cells are the major source of CXCL9. PGE2 impairs IFN-g
mediated CXCL9 and CXCL10 release from MCF-7 and MDA-MB 231 cells, and inhibition of endogenous
cyclooxygenases by indomethacin or ASA correspondingly increases this secretion. Otherwise, high concentrations
of the Cyclooxygenase-2 (COX-2) specific antagonist celecoxib have opposite effects and impair CXCL9 and CXCL10
release. In human breast cancer tissue specimens there is an inverse correlation between COX-2 overexpression
and CXCL9 concentration, suggesting that the observed in vitro effects are of importance in vivo as well.
Conclusions: Suppressing endogenous PGE2 synthesis by cyclooxygenase inhibition increases CXCL9 and CXCL10
release from breast cancer cells and is therefore a pharmacologic candidate to enhance intratumoral immune
infiltration. Yet, to this end the unselective COX inhibitors ASA and indomethacin seem preferable to celecoxib that
at higher concentrations reduces CXCR3 ligand release most probably due to COX independent mechanisms.
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Introduction
Successful immunotherapeutic strategies in cancer treat-
ment require an effective infiltration of the tumor by
tumor-suppressive immune cells. Immunotherapeutic
approaches can therefore be impeded by an unfavorable
composition of the intratumoral immune milieu: while
regulatory T cells (Tregs) and myeloid-derived suppressor
cells (MDSCs) repress a successful immune intervention
and promote tumor progression, natural killer (NK)
cells and T helper (Th) 1 CD4+/CD8+ lymphocytes are
potent mediators of anti-tumor activity [1-3]. However,
insufficient migration of this type of immune cells
towards the tumor microenvironment will not allow
attacking of cancer cells by these cells in patients with
advanced tumors [4,5].
The CXCR3 chemokine receptor is preferentially
expressed on the surface of NK cells or Th1 tumor-sup-
pressive T lymphocytes and is responsible for their che-
motactic recruitment into the tumor tissue [6,7].
Correspondingly, high intratumoral concentrations of
the interferon (IFN)-g-inducible chemokines CXCL9 and
CXCL10, two of the CXCR3 ligands, are associated with
increased immune infiltration and improved survival in
patients with solid malignancies [8-13]. In human breast
cancer, we and others have shown that a high expres-
sion of the CXCL9 mRNA correlates with an increased
number of infiltrating lymphocytes and a better
response to chemotherapy [14,15]. Furthermore, in a
mouse model transfection of murine breast cancer cells
with CXCL9 increases chemotactic T cell recruitment,
impairs tumor growth, prevents lung metastasis forma-
tion, and prolongs survival [16]. Raising the intratumoral
concentration of CXCR3 ligands is therefore a feasible
therapeutic option to improve immune intervention.
Still, origin and regulation of CXCR3 chemokines in
human breast cancer are poorly understood.
A conceivable way to shift the tumor microenviron-
ment to a more tumor-suppressive Th1 milieu is modu-
lation of the cyclooxygenase (COX) system. Two
isoenzymes, constitutively expressed COX-1 and induci-
ble COX-2, are found in human breast tumors. COX-2
overexpression is associated with reduced infiltration of
tumor-suppressive immune cells, and COX inhibition in
turn enhances immunosurveillance [17-19]. Moreover,
prostaglandin E2 (PGE2), the major product of COX in
tumors, promotes tumor growth at least in part by redu-
cing the activity of NK cells and expanding MDSCs and
Tregs [20,21]. In breast cancer models, both COX inhibi-
tion and PGE2 receptor antagonism suppress local
tumor growth and metastatic spread in an IFN-g and T
cell- or NK cell-dependent manner [22-24].
In light of these findings, we explored whether com-
ponents of the COX pathway would be pharmacologic
candidates to enhance CXCR3 ligand concentration in
human breast cancer. We now demonstrate that PGE2
inhibits IFN-g induced CXCL9 and CXCL10 secretion
from breast cancer cells and that, conversely, the COX
inhibitors acetylsalicylic acid (ASA) and indomethacin
augment this release. Inverse correlation of COX
expression and intratumoral CXCL9 concentration in
human breast cancer samples indicate the relevance in
vivo. The COX-2-specific inhibitor celecoxib, however,
has the opposite effects at higher concentrations impli-
cating that the choice of the appropriate COX inhibitor
for clinical use seems to be decisive. In summary, our
results provide a mechanistic link between the COX
pathway and a reduced infiltration of tumor-suppressive
lymphocytes in breast cancer through the modulation of
intratumoral CXCR3 chemokine release.
Materials and methods
Reagents and cell lines
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf
serum (FCS), gentamycin, 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES), and glutamine were
from Gibco Life Technologies (Gaithersburg, MD, USA);
recombinant human interferon gamma (IFN-g) and
recombinant human TNF-a were from PeproTech
(Hamburg, Germany); prostaglandin E2, indomethacin,
and celecoxib were from Cayman Chemicals (Ann
Arbor, MI, USA) and reconstituted in dimethyl sulfoxide
(DMSO); acetylsalicylic acid (ASA) was from Sigma (St.
Louis, MO, USA) and reconstituted in phosphate buf-
fered saline (PBS); bovine serum albumin was from
Sigma (St. Louis, MO, USA). Antibodies to human anti-
gens: monoclonal mouse anti-CXCL9 antibody (clone
49106, R&D Systems, Minneapolis, MN, USA); mono-
clonal mouse anti-COX-1 (clone COX111, Invitrogen,
Camarillo, CA, USA); monoclonal mouse anti-COX-2
(clone CX229, Cayman Chemicals, Ann Arbor, MI,
USA); monoclonal mouse anti-glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH, clone 6C5, Millipore,
Billerica, MA, USA); horseradish peroxidase-conjugated
goat anti-mouse IgG (Jackson ImmunoResearch, Bur-
lington, ON, USA). All other chemicals were of analyti-
cal grade and obtained from Merck (Darmstadt,
Germany) or Sigma (St. Louis, MO, USA).
MCF-7 and MDA-MB 231 human breast cancer cell
lines (American Type Culture Collection, Manassas, VA,
USA) were cultured in a humified 5% CO2 atmosphere
at 37°C in DMEM supplemented with glutamine, 10%
FCS, 10 mM HEPES, and 20 μg/mL gentamycin.
Human tissue samples and patient characteristics
Fresh-frozen tissues from 60 breast cancer patients who
were treated at the Department of Gynecology and
Obstetrics, Technical University Munich, between 1991
and 2004 were selected. The study was approved by the
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local ethics committee, all patients had given written
informed consent. All tumors came from nodal-positive,
non further metastasized tumors that were estrogen
receptor positive (N+, M0, ER+).
Immunohistochemistry
Immunohistochemistry was performed on 4 μm thick
paraffin sections from invasive breast cancer tissue spe-
cimens (n = 20) obtained from patients treated at the
Department of Gynecology and Obstetrics, Technical
University Munich. Briefly, sections were deparaffinized
by treatment with xylene followed by a graded series of
ethanol (100% to 70%) in distilled H2O and subjected to
heat-induced epitope retrieval in citrate buffer (pH 6.0).
Endogenous peroxidase was blocked using 3% H2O2 in
distilled H2O, 20 minutes, room temperature, followed
by antigen blocking with 5% goat serum in 50 mM Tris-
HCl, pH 7.4, 10 minutes, room temperature. The sec-
tions were then incubated with mouse anti-CXCL9
diluted to a final concentration of 20 μg/mL in antibody
diluent (DAKO, S2022), one hour, room temperature.
For detection of primary antibody binding the Zyto-
Chem Plus HRP Broad Spectrum Kit was employed
(Zytomed Systems, Berlin, Germany) according to the
manufacturer’s instruction. Sections were washed thor-
oughly between incubations and counterstained with
hematoxylin.
Determination of CXCL9 and CXCL10 secretion from
breast cancer cells
MCF-7 and MDA-MB 231 cells were plated on 24-well
culture plates and grown to 70 to 80% confluency before
they were washed in PBS and starved for 24 hours in
serum-free medium. The medium was then replaced by
serum-free medium and test reagents added as indicated.
In case of inhibition studies the cells were preincubated
with prostaglandin E2 or cyclooxygenase inhibitors (indo-
methacin, ASA, celecoxib) for 30 minutes before addition
of IFN-g. After 24 hours the supernatants were collected
and stored at -20°C until further use. In each experiment,
at least six wells were stimulated. Subsequently the cul-
ture supernatants were subjected to ELISA for determi-
nation of chemokine concentrations. The DuoSet ELISA
Kits DY392 and DY266 (R&D Systems, Minneapolis,
MN, USA) were used for the determination of CXCL9
and CXCL10, respectively, according to the manufac-
turer’s instructions.
MTT assay
Viability of cells subjected to cytokines, cyclooxygenase
inhibitors, or prostaglandin E2 was assessed using the
MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide, Sigma-Aldrich, St. Louis, MO, USA).
A sample of 5 × 103 MCF-7 or 7 × 103 MDA-MB 231
cells were plated into each well of a 96-well plate and
cultured for 24 hours. After starving in serum-free med-
ium for another 24 hours, cells were stimulated with the
respective stimulants for 24 or 48 hours as indicated in
the results section. Then, 20 μL of MTT was added to a
final concentration of 200 μg/mL and the cells incu-
bated at 37°C for two hours, followed by the addition of
100 μL DMSO. Absorbance was measured at 590 nm.
Quantification of CXCL9 concentration in tumor tissue
extracts
Breast cancer tumor tissue specimens were obtained at
surgery, inspected by a pathologist, and then stored in
liquid nitrogen until further use. Tumor tissue homoge-
nates were prepared as described previously [25]. Total
protein concentrations were determined applying the
BCA Protein Assay Kit (Pierce, Thermo Scientific, Rock-
ford, IL, USA). Tissue Extracts were diluted 1:5 in PBS/
1% BSA and then subjected in duplicates to DuoSet
ELISA kit (R&D Systems, Minneapolis, MN, USA).
Western blot analysis
After incubation of the tumor cells with stimulants cul-
ture medium was removed and cells washed with ice-
cold PBS and immediately lysed in SDS-PAGE sample
buffer containing 1% (w/v) Triton X-100, 150 mM
NaCl, 1 mM EDTA, 50 mM HEPES, 1 mM sodium
vanadate, and complete protease inhibitor cocktail
(Roche, Mannheim, Germany). Samples were kept on
ice for 20 minutes, subjected to ultrasound (2 × 10 sec-
onds, 4°C), and stored at -20°C until further use. Total
protein concentration was determined using the BCA
Protein Assay Kit (Pierce, Thermo Scientific, Rockford,
IL, USA). Equal amounts of protein (60 μg) were sepa-
rated by 10% SDS-PAGE and blotted onto polyvinyli-
dene fluoride (PVDF) membranes using a semi-dry
transfer apparatus (Biometra, Göttingen, Germany).
Blots were blocked with 5% (wt/vol) milk powder
(Sigma, St. Louis, MO, USA) containing PBS/0.5%
Tween 20 (w/v) (PBS-T) and then incubated at 4°C
overnight with primary antibodies (anti-COX-1 0.5 μg/
mL, anti-COX-2 0.5 μg/mL, anti-GAPDH 0.1 μg/mL).
Following washing with PBS-T and incubation with
horseradish peroxidase-coupled anti-mouse IgG (diluted
1:10.000 in 5% milk powder in PBS-T), one hour, room
temperature, the blots were washed and the antibody
reaction visualized by enhanced chemoluminescent
detection (Amersham Biotech, Uppsala, Sweden). Blots
were exposed to Kodak X-Omat AR-5 film (Eastman
Kodak Co., Rochester, NY, USA).
Statistical analysis
Results were taken from at least three independent
experiments and analyzed using the Mann-Whitney test
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(SPSS Statistics Software, Zurich, Switzerland, Version
17.0). Results are given as mean ± standard deviation of
the mean, if not indicated otherwise. Statistical signifi-
cance was defined as * P≤0.05, ** P≤0.005, or ***
P≤0.0005.
Results
Within the tumor microenvironment, CXCL9 is
predominantly expressed by breast cancer cells
Datta et al. reported that CXCL10 is expressed in breast
cancer cells [26]. To find out if this holds true for
CXCL9 as well, we performed immunohistochemical
analyses of primary breast cancer tissue sections using a
monoclonal antibody to CXCL9 (Figure 1a). By this
approach we show that CXCL9 is localized predomi-
nantly in the cytoplasm of breast cancer cells. The
majority of tumor samples (17 of 20) showed CXCL9
immunoreactivity to variable degrees (Figures 1c to 1e).
In most samples, CXCL9 protein was also expressed by
endothelial cells (15 of 20 samples, Figure 1f) and was
found in the extracellular matrix (ECM, 17 of 20 sam-
ples), which is supporting data by others showing that
CXCR3 ligands may bind to the ECM [27].
IFN-g and TNF-a induce CXCR3 ligand release from
human breast cancer cell lines
To study the release of the two chemokines CXCL9 and
CXCL10 from breast cancer cells we investigated regula-
tion of protein secretion by supplying the inflammatory
cytokines IFN-g and TNF-a, which are both present in
breast cancer tissues and known to induce CXCR3
ligands in other cell types [6,28,29]. CXCL9 and
CXCL10 were not released into the culture medium of
unstimulated MCF-7 or MDA-MB 231 breast cancer
cells, whereas IFN-g induced both cell types for CXCL9/
10 secretion in a dose-dependent manner (Figures 2a to
2d). Stimulation with 50 ng/mL IFN-g yielded circa five-
fold higher CXCL9 and 20-fold higher CXCL10 release
by MDA-MB 231 than by MCF-7 cells. TNF-a alone
had a measurable effect on CXCL10 release only, but
not on CXCL9 (Figures 2c and 2d). The combination of
10 ng/mL TNF-a and 10 ng/mL IFN-g, however,
revealed a strong synergistic effect of both cytokines:
CXCL9 secretion increased eight-fold and seven-fold in
MCF-7 and MDA-MB 231 cells, respectively, CXCL10
release increased 64-fold and three-fold, respectively,
compared with stimulation with 10 ng/mL IFN-g alone
(Figures 2a to 2d).
PGE2 inhibits IFN-g induced CXCL9 and CXCL10 secretion
To approach our hypothesis that the COX system will
have a significant impact on the CXCR3 ligand milieu of
breast tumor environment we first investigated the effect
of exogenous PGE2 on CXCL9 and CXCL10 release.
IFN-g exposed breast cancer cells were used as controls
in the subsequent experiments, because IFN-g is a
strong inducer of CXCR3 ligand expression, and the
anti-tumor effects of CXCL9 and CXCL10 have been
shown to be IFN-g dependent in mouse models
[16,30,31]. Based on the previous results (Figure 2), we
stimulated MCF-7 cells with 50 ng/mL IFN-g and
MDA-MB 231 cells with 2.5 ng/mL IFN-g to induce
chemokine concentrations in the sensitivity range of our
ELISA kits. Addition of 10 μM PGE2 30 minutes prior
to IFN-g stimulation reduced the CXCL9 and CXCL10
secretion by MCF-7 cells approximately 1.6-fold and 2-
fold, respectively (Figure 3a). In MDA-MB 231 cells this
reduction was less pronounced: using 2.5 ng/mL IFN-g
stimulated cells as control, exposition to 10 μM PGE2
30 minutes prior to IFN stimulation reduced the
CXCL9 production approximately 1.25-fold (Figure 3a).
Time-dependent experiments demonstrated that reduc-
tion of CXCL9 by MCF-7 cells was greatest after 18
hours, by MDA-MB 231 cells after 24 hours (Figure 3b).
Unselective COX inhibitors induce CXCL9 and CXCL10
release from breast cancer cells
As both MCF-7 and MDA-MB 231 cancer cell lines
have been shown to express different COX isoenzymes
[32], we expected that blocking endogenous PGE2 by
COX inhibitors would increase CXCR3 ligand secretion.
Whereas both MCF-7 an MDA-MB 231 cells expressed
COX-2, COX-1 was expressed by MDA-MB 231 cells
only (Figure 4a). In the following, the cells were prein-
cubated with 10 μM or 30 μM of ASA or indomethacin
for 30 minutes before IFN-g was added. Indomethacin
increased CXCL9 release in a dose-dependent manner
approximately two-fold and 1.6-fold in MCF-7 (Figure
4b) and MDA-MB 231 cells (Figure 4d), respectively,
and CXCL10 secretion approximately 2.5-fold in MCF-7
cells (Figure 4c) and 2.0-fold in MDA-MB 231 cells
(Figure 4e). ASA increased CXCL9 secretion 1.5-fold
and 1.2-fold in MCF-7 and MDA-MB 231 cells, respec-
tively (Figures 4b and 4d) and the CXCL10 secretion
2.8-fold and 2.3-fold (Figures 4c and 4e).
The COX-2 selective inhibitor celecoxib shows differential
effects on CXCR3 ligand secretion
Subsequently we tested whether the COX-2 specific
inhibitor celecoxib would also raise CXCL9 or CXCL10
release from MCF-7 or MDA-MB 231 breast cancer
cells. However, the expected increase of CXCL9 in the
supernatants was only observed at low concentrations.
At elevated concentrations of celecoxib we observed a
decline in CXCL9 secretion to approximately 0.7-fold of
control in both cell lines by 30 μM celecoxib (Figures 5a
and 5c). CXCL10 release was increased in a concentra-
tion-dependent manner, but in MCF-7 cells we also
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Figure 1 Expression of the CXCL9 protein in tissue specimens from patients with invasive breast cancer . (a) Representative
immunohistochemical staining with the monoclonal antibody to CXCL9 showing staining predominantly in the cytoplasm of tumor cells and in
the extracellular matrix. (b) No immunoreactivity was seen using isotype matched controls. Different breast cancers showed (c) strong, (d) weak,
or (e) no CXCL9 expression. Besides expression in cancer cells and the extracellular matrix, CXCL9 was also found in endothelial cells (arrows in
f). Nuclei were counterstained with hematoxylin. Bars in c to e, 200 μm.
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observed a decline again when using concentrations
above 1.0 μM (Figure 5b). This decline was not observed
in MDA-MB 231 cells (Figure 5d). Maximum increase
in CXCL9 and CXCL10 secretion from MCF-7 cells was
archieved using 0.1 μM celecoxib (approximately 1.7-
fold) and 1.0 μM celecoxib (approximately 2.7-fold),
respectively.
Modulation of CXCR3 ligand secretion by COX inhibition
or PGE2 is not attributable to changes in cell viability
To rule out the possibility that the changes in CXCL9
or CXCL10 release were due to altered cell proliferation
or apoptosis rather than to intracellular regulation, we
investigated viability of MCF-7 and MDA-MB 231 cells
by MTT assays. Even after 48 hours no significant
change in cell viability in the presence of PGE2 or
unselective or selective COX inhibitors was observed
(Figure 6).
Inverse correlation of COX overexpression and CXCL9
concentration in human breast cancer
To explore whether the observed regulation of CXCL9
by COX could be important also in vivo, we prepared
tissue extracts from a total of 46 fresh-frozen human
breast cancer tumor tissue samples and determined
COX-1 and COX-2 expression by western blot and sub-
sequent densiometric analysis (Figure 7a). CXCL9 levels
were quantified by ELISA (CXCL9 protein concentra-
tions ranged between less than 0.01 pg and 16.8 pg
CXCL9/μg total protein). For each COX isoenzyme
samples were divided into a low and a high expressing

























































































































































Figure 2 Induction of CXCR3 binding ligands in human breast cancer cell lines by inflammatory cytokines. MCF-7 and MDA-MB 231
breast cancer cells were starved in serum-free medium for 24 hours and then exposed for another 24 hours to the IFN-g and TNF-a
concentrations indicated. Supernatants were harvested, and CXCL9 and CXCL10 concentrations determined by ELISA. Results from at least three
independent experiments are presented. (a to d) In each experiment cells in at least six different wells were stimulated in parallel. IFN-g induced
both chemokines in a dose-dependent manner. (c and d) In contrast, TNF-a had a measurable effect on CXCL10 only. (a to d) Addition of TNF-
a to IFN-g potentiates the interferon effect. This is more pronounced in MCF-7 than in MDA-MB 231 cells. Statistical significance was defined as *
P≤0.05, ** P≤0.005, or *** P≤0.0005.
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Figure 3 Suppression of CXCL9 and CXCL10 secretion by PGE2 in human breast cancer cell lines. (a) MCF-7 and MDA-MB 231 cells were
exposed to 10 μM PGE2 for 30 minutes prior to addition of 50 ng/mL or 2.5 ng/mL IFN-g, respectively (filled bars). Stimulation with IFN-g and
DMSO served as control (dashed bars). After 24 hours, supernatants were collected and CXCR3 ligand concentrations measured by ELISA. Results
from at least three independent experiments are presented. In each experiment cells in at least six different wells were stimulated in parallel. In
MCF-7 cells, PGE2 reduced the CXCL9 secretion to 60.7% ± 4.7% and the CXCL10 secretion to 48.3% ± 6.3%. In MDA-MB 231 cells, this inhibiton
was less pronounced and reached statistical significance only for CXCL9 (77.8% ± 9.3%). (b) Representative experiment showing the time-
dependence of CXCL9 release from MCF-7 (left) and MDA-MB 231 cells (right). The greatest inhibition of CXCL9 release by PGE2 (10 μM) was
seen at 18 hours after stimulation in MCF-7 and at 24 hours in MDA-MB 231 cells. MCF-7 and MDA-MB 231 cells were stimulated with 50 ng/mL
and 2.5 ng/mL IFN-g, respectively.
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the data by Soslow et al. reporting that 65% of breast
cancers overexpress COX-2 [33]. As very conflicting
data exist for COX-1 overexpression in breast cancers
we divided the samples in two equally large groups.
With regard to COX-1, there was a trend towards
reduced CXCL9 expression in high-expressing tumors
(87.8% ± 13.4%, nlow = 22, nhigh = 21, Figure 7b). With
regard to COX-2, the CXCL9 concentration in the high-
expressing group was only half of that of low-expressing
tumors (56.5% ± 13.9%, nlow = 12, nhigh = 17, P <0.026,
Figure 7c). Similiar results were obtained when dividing
the samples according to the data by Ristimaki et al.
[34] reporting that 37% of breast cancers overexpress
COX-2 (55.0% ± 10.9%, nlow = 17, nhigh = 12, P = 0.09).
Discussion
In this study, we have identified the COX pathway as a
potential pharmacologic candidate to enhance the intra-
tumoral accumulation of CXCL9 and CXCL10 levels in
breast cancer. Earlier studies have highlighted the
importance of CXCR3 ligands in recruiting NK cells, as
well as CD4+ or CD8+ T lymphocytes to the tumor site
[7,30,35,36]. Although the three CXCR3 ligands CXCL9-
11 have redundant functions for the most part, for yet
unknown reasons CXCL9 emerges as the preferred
CXCR3 ligand, mediating lymphocytic infiltration and
growth suppression of tumors [30,31]. This is in agree-
ment with clinical studies in human breast cancer iden-
tifying CXCL9, rather than CXCL10 or CXCL11, as a
potential biomarker for diagnosis of breast cancer and
therapy response, suggestive of its protective role in
breast cancer biology [14,15,37]. These reasons led us to
focus predominantly on CXCL9. Our immunohisto-
chemical breast cancer studies localize CXCL9 to cancer
cells (Figure 1). Datta et al. reported similiar findings for
CXCL10 [26], emphasizing that these cells are a major
source of CXCR3 ligands in the breast tumor microen-
vironment. However, our results also show CXCL9
expression in endothelial cells. As endothelial cells seem
to produce CXCR3 chemokines in response to similiar
stimuli as cancer cells they might also participate in
modulating immune infiltration in breast cancer [38].
In our study, IFN-g induced CXCL9 and CXCL10
secretion in a dose-dependent manner, whereas TNF-a
induced CXCL10 only. Induction of CXCL10 by TNF-a





























































































































































































Figure 4 Induction of CXCR3 ligand release from breast cancer cells by unselective cyclooxygenase inhibitors. (a) Expression of COX-1
and COX-2 isoenzymes in MCF-7 and MDA-MB 231 cells. Representative western blots of lysates prepared from unstimulated and IFN-g (10 ng/
mL, 24 hours) exposed cells using monoclonal antibodies against the two COX isoenzymes. MCF-7 cells showed only weakly inducible COX-2
expression, whereas MDA-MB 231 cells expressed both COX-1 and COX-2, the latter one further induced by IFN-g. In MCF-7 and in MDA-MB 231
cells, the COX-2 directed antibody shows two bands at 72 and 74 kDa which represent two different glycosylation states [62]. (b to e) MCF-7
and MDA-MB 231 cells were preincubated with vehicle or various concentrations of ASA or indomethacin, 30 minutes before IFN-g (50 ng/mL
for MCF-7, 2.5 ng/mL for MDA-MB 231) was added. After 24 hours, cell supernatants were collected and CXCR3 ligand concentrations
determined by ELISA. In both cell lines, both unselective COX inhibitors significantly enhance CXCL9 or CXCL10 secretion. (c and e) This effect
was more pronounced for CXCL10, where the induction was about two- to three-fold of the control value. (b and d) For CXCL9, indomethacin
was a more potent inducer than ASA. Asterisks mark significant differences compared with the control.
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eosinophils and corneal keratocytes [39,40]. TNF-a
potentiated IFN-g induction of both chemokines, an
effect which has been described for other cell types as
well and may be ascribed to the synergistic action of
transcription factors such as STAT-1a (activated by
IFN-g) and NF-B (activated by TNF-a) or to the action
of transcription coactivators such as CREB binding pro-
tein [41]. For the subsequent regulatory experiments on
the effects of PGE2 and COX inhibitors we decided to
use IFN-g stimulated cells as baseline controls, because
it is the most potent inducer of both CXCR3 chemo-
kines and a prerequisite for the immune-mediated
tumor-suppressive effects of COX inhibitors in murine
breast cancer models [23].
Our results demonstrate that PGE2 inhibits, whereas
COX inhibitors induce the release of CXCL9 and
CXCL10 from breast cancer cells. This is in line with
similar results described for epidermoid tumor cells and
various kinds of immune cells [42-44]. Both effects were
more pronounced in MCF-7 than in MDA-MB 231
cells, although the latter ones expressed higher levels of
cyclooxygenases (Figure 4, [32]), so that a higher effect
of COX inhibition was expected. Although not the sub-
ject of the present study, one may assume that a higher
activity of the PGE2 prostanoid receptors (EP1-EP4) and
their downstream targets in MCF-7 cells is responsible
for this difference rather than the higher intrinsic PGE2
production in MDA-MB 231 cells. Both cell lines do
express all four EP prostanoid receptors [45].
Our findings provide a mechanistic link between the
COX pathway and CXCL9/CXCL10 chemokine secre-
tion into the tumor microenvironment of human breast
tumors. The inhibition of CXCR3 ligands might be
added to the mechanisms by which PGE2 promotes
tumor escape from the immune system [46]. Several
mouse tumor models other than breast cancer have col-
lectively demonstrated that COX inhibition enhances
















































































































































Figure 5 Differential modulation of CXCR3 ligand release by the COX-2 specific inhibitor celecoxib. MCF-7 and MDA-MB 231 cells were
preincubated with the indicated concentrations of celecoxib 30 minutes prior to IFN-g addition (50 ng/mL for MCF-7, 2.5 ng/mL for MDA-MB
231). After 24 hours, cell supernatants were collected and CXCR3 ligand concentrations measured by ELISA. (a and b) In MCF-7 cells, celecoxib
increases CXCL9 and CXCL10 release at low concentrations (0.1 and 1.0 μM), but this increase deminishes at higher concentrations. (a and c) At
30 μM celecoxib a significant reduction in CXCL9 secretion was seen. (d) The CXCL10 release from MDA-MB 231 cells rises in a dose-dependent
manner with increasing celecoxib concentrations. Asterisks mark significant differences compared with the control, if not indicated otherwise.
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growth by raising the number of infiltrating Th1 lym-
phocytes [17-19,47]. Moreover, these studies have
detected an increased expression of Th1 cytokine
mRNA, including those of murine CXCL9 and CXCL10
homologs after COX inhibition. Fulton et al. reported
that inhibition of COX-1 and COX-2 leads to reduced
breast tumor growth and reduced metastatic spread in
mice [48]. This inhibition depends on CD4+ and CD8+
T cells in case of local tumor control and NK cell activ-
ity and IFN-g in case of metastatic control [23]. Preincu-
bation of the cancer cells with COX inhibitors prior to
injection into the animals is sufficient to cause anti-
tumor actitvity, which supports our observation that the
tumor cells are the source of the COX-mediated effect
[48]. Although determination of chemokine levels was
not subject of these studies, our results offer an addi-
tional explanation in that enhanced CXCR3 ligand
secretion from cancer cells contributes to this immune-
mediated anti-cancer effect of COX inhibitors. Clinical
data by Denkert et al. further support our interpretation
which show a significant correlation between CXCL9
mRNA levels and infiltrating T lymphocytes with favor-
able chemotherapy response in breast cancer patients
[14].
Our findings demonstrate a differential regulation of
CXCL9 and CXCL10 secretion by COX inhibitors.
Although ASA and indomethacin increased the release
of CXCL9 and CXCL10, the COX-2-specific inhibitor
celecoxib had this effect only at low concentrations. The































































































Figure 6 Influence of reagents on breast cancer cell viability. MTT assays were performed to determine the influence of the stimulants used
in this study on cell viability of MCF-7 and MDA-MB 231 cells. Even at 48 hours no significant difference in cell viablity was observed, showing
that the PGE2 and COX inhibitor effects are not attributed to altered proliferation or apoptosis.
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Figure 7 Correlation between cyclooxygenase and CXCL9 expression in human breast cancer tissue samples. Homogenates were
prepared from deep-frozen breast cancer tissue samples and analyzed for COX-1 and COX-2 expression by western blot analysis. Panel a shows
representative immunoblots with high (first lane) and low (second lane) expression of both enzymes. For both cyclooxygenase isoenzymes
samples were divided into a low and a high expressing group (see text for further details), and CXCL9 concentration was determined in all
samples by ELISA. There was a trend towards lower CXCL9 expression in the high COX-1 expressing group (b; nlow = 22, nhigh = 21), but a
significantly reduced CXCL9 concentration in highly COX-2 expressing breast cancers (c; nlow = 12, nhigh = 17). COX-2 overexpressing breast
cancers display only half of the average CXCL9 concentration found in low-expressing cancers (56.5% ± 13.9%). (b and c) CXCL9/total protein
ratio is presented as arbitrary units with 1.0 set as the arithmetic mean of the low expressing group. Horizontal lines in b and c represent the
arithmetic mean.
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concentrations on CXCR3 ligand release remain unclear,
but a possible explanation is that the COX inhibitory
effects of celecoxib at high concentrations are superim-
posed by its COX-independent effects, particularly the
inactivation of NF-B signalling [49]. Similiar findings
have been reported for the NSAID sulindac, that, in
contrast to ASA, impaired CXCL9 mRNA synthesis in
mouse macrophages [50]. Moreover, in a murine model
of colorectal cancer, celecoxib showed COX-indepen-
dent anti-tumor activity and even decreased the number
of infiltrating lymphocytes [51], consistent with an
impairment of CXCR3 ligand release.
Elevated intratumoral COX and PGE2 levels in breast
cancer are known to be associated with poor outcome
and development of distant metastases [34,52,53]. We
observed an inverse correlation between COX-2 overex-
pression and intratumoral CXCL9 concentration and a
trend towards lower CXCL9 expression in COX-1 over-
expressing breast cancer tissues. This is in line with pre-
clinical data demonstrating that COX-2, rather than
COX-1, is inducing PGE2 synthesis in breast tumors
[54]. In this context, it might be interesting to analyze
tumor tissue samples of breast cancer patients that took
NSAIDs on a regular basis to see if CXCL9 expression
is different from patients who did not, but such investi-
gations were not in focus of the analysis presented.
In conclusion, our results show that COX inhibition is
a feasible way to improve immunosurveillance in human
breast cancer by inducing intratumoral CXCR3 binding
chemokines. To this end, unselective NSAIDs such as
indomethacin or aspirin might be more suitable than
COX-2-specific agents. The need for COX inhibiton as
a component of breast cancer therapy is further
endorsed by supporting clinical data. Although the use
of NSAIDs in the prevention of breast cancer has been
debated for years, albeit with conflicting results [55-58],
recent retrospective analyses of large clinical trials have
shown that NSAID intake during the course of the can-
cer disease is associated with a significantly decreased
risk of disease recurrence and breast cancer related
death [59-61]. Yet, randomized prospective trials are
needed to clarify the benefit of COX inhibition in breast
cancer therapy and to discover the underlying mechan-
isms in vivo.
Conclusions
PGE2 inhibits IFN-g-induced release of CXCL9 and
CXCL10 in human breast cancer cells. Conversely, the
COX inhibitors ASA and indomethacin augment this
secretion, whereas the COX-2 specific antagonist cele-
coxib has differential effects and inhibits CXCR3 ligand
release at higher concentrations. In human breast cancer
samples, CXCL9 concentrations correlate inversely with
COX-2 expression. These results show that unselective
COX inhibitors are a feasible pharmacologic way to
raise the intratumoral levels of CXCR3 ligands in
human breast cancer with the objective to increase
tumor infiltration by tumor-suppressive immune cells
and improve the outcome of breast cancer therapy.
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